CUBE LABS SPA: management transactions · Italy · Consob

About CUBE LABS SPA

Cube Labs S.p.A. is an Italian healthcare technology venture builder listed on Borsa Italiana (FTSE MIB) through the Euronext Growth Milan Professional segment. Founded in 2013, the company was built around a focused investment and incubation thesis: turning high-quality academic research into commercially viable companies and products in the life sciences sector. Its registered office is in Rome, with secondary offices in Maglie and Milan, underscoring a primarily Italian operating base while retaining an outward-looking, international ambition. Cube Labs’ business model combines spin-off creation, equity participation, operational support and R&D project development. In practice, the company acts as a bridge between universities, research institutes, clinicians and the market, contributing capital, governance, development expertise and access to industrial partners. Its core exposure is concentrated in medtech, biotech, pharma and broader healthcare technologies. The most visible portfolio and project names include Adamas Biotech, DTech, Biodiapers, Cartilago, Lipovexa and FluoDetect, alongside initiatives connected to digital platforms, medical devices, therapeutic applications and nutraceutical solutions. From a competitive standpoint, Cube Labs differentiates itself from a conventional financial investor by using a highly hands-on venture-building approach. This niche positioning allows it to source intellectual property originating in academia and structure it into dedicated vehicles with medium-term value-creation potential. The strategy is attractive in a European context where academic-to-commercial translation is still fragmented and under-monetised. For investors, that creates an interesting growth optionality profile, but also a higher risk level than a mature industrial company, given the dependence on project execution, regulatory pathways and financing rounds. Recent highlights include continued capital increases, the creation of new spin-offs in 2024, public and scientific support for certain portfolio companies, and new R&D partnerships in Italy and abroad. Cube Labs has also announced progress on patent protection, industrial collaboration and commercial development, notably in digital health and regenerative technologies. Overall, the stock remains a thematic small-cap growth story, driven by its pipeline, its ability to convert scientific IP into enterprise value, and its capital allocation discipline. The company’s market listing on Borsa Italiana (FTSE MIB) in Italy gives it visibility, but the investment case remains anchored in long-duration venture-building economics rather than short-term earnings power.